1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
AcuCort AB

AcuCort AB

ACUC.ST
AcuCort ABSE flagStockholm Stock Exchange
0.65
SEK
+0.04
- -
152.39MMarket Cap
AcuCort AB
ACUC.ST
(Stockholm Stock Exchange)

Recent

price

0.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
- -
- -
Revenue per Share
-0.24
-0.17
-0.15
-0.39
-0.4
-0.27
-0.25
-0.24
-0.4
-0.14
-0.16
-0.12
-0.11
Basic EPS, GAAP
-0.43
-0.34
-0.21
- -
- -
- -
-0.33
-0.29
-0.5
-0.18
-0.25
-0.11
-0.09
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.04
1.48
1.15
1.17
-0.33
0.41
-1.4
-0.98
-1.75
-0.86
-0.86
-0.34
-0.34
Book Value per Share
0.2
0.02
0.27
0.89
0.57
1.08
0.76
0.73
0.38
0.09
-0.01
0.11
0.07
Tangible Book Value per Share
13
13
13
12
15
31
31
46
37
99
109
218
245
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-2,575.56
-3,856.33
-3,940.8
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4
8
8
Depreciation Expense
-3
-2
-2
-5
-6
-8
-8
-11
-15
-14
-17
-26
-26
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-2,577.48
-3,812.23
-3,902.65
Profit Margin (%)
3
- -
3
11
9
33
23
34
14
9
-1
24
18
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
21
20
20
30
25
54
46
60
46
48
41
64
57
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-22.48
-11.63
-32.42
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
234
234
234
Market Capitalization
139
146
156

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
35
28
23
Cash, Cash Equivalents & STI
34
27
21
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
3
5
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.65%
10.49%
56.04%
Free Cash Flow
- -
22.03%
-8.63%
Net Income, GAAP
33.62%
29.32%
50.53%
Sales/Revenue/Turnover
- -
- -
1.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
1
- -
1
2025
- -
- -
1
- -
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
-0.03
-0.02
-0.05
-0.16
2025
-0.03
-0.03
-0.02
-0.03
-0.12
2026
-0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
AstraZeneca Pharma India Limited (ASTRAZEN.BO)
Ionic Brands Corp. (IONKF)
Enzymatica AB (publ) (ENZY.ST)
Petros Pharmaceuticals, Inc. (PTPI)
Collegium Pharmaceutical, Inc. (COLL)
Toho Holdings Co., Ltd. (8129.T)
Business
AcuCort AB (publ) (ACUC.ST) develops and commercializes innovative oral dissolvable films based on glucocorticoid dexamethasone for treating acute allergic conditions; its primary product Zeqmelit, a fast-dissolving oral film placed on the tongue, targets severe and acute allergic reactions, croup in children, chemotherapy-induced nausea and vomiting, and supplemental oxygen therapy for COVID-19 patients. Zeqmelit received marketing approval in Sweden, Denmark, Norway and Finland, where it operates under a user-friendly, patented administration form previously marketed as ISICORT in Sweden; the company pursues registrations in additional prioritized markets through partnerships with global licensees and distributors. Founded in 2006 and headquartered at Medicon Village in Lund, Sweden, AcuCort focuses on repurposing well-documented substances into smart drugs addressing unmet medical needs in high-commercial-interest areas, with shares listed on Spotlight Stock Market since 2017. In November 2022, AcuCort signed its first commercial agreement for Zeqmelit with Kamada Ltd. for the Israeli market; recent developments include a rights issue in early 2025 supported by CEO Jonas Jönmark's additional SEK 1 million subscription, management strengthening in October 2024 with Anna Chérouvrier Hansson as Business Development Director ahead of expanded commercialization, and quarterly reports through Q2 2025 highlighting strategic gearing up of its commercialization team. The company prioritizes short-development-cycle products with high innovation in respiratory and acute care segments, primarily serving healthcare professionals and patients across Nordic countries and select international markets via its distribution network.